Search
Nuvation Bio Inc
NUVBAdd to Watchlist
6.330USD
-0.360-5.37%
Close 07-31 16:00（ET）Quotes delayed by 15 min
2.20BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Nuvation Bio Inc is 8.18, ranking 162 out of 385 in the Biotechnology & Medical Research industry. The average price target is 10.00, with a high of 12.00 and a low of 8.00.
Analyst Rating
Based on
11
analysts
Buy
Current Rating
12.700
Target Price
+100.63%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Nuvation Bio Inc
NUVB
11
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
Kymera Therapeutics Inc
KYMR
24
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Nuvation Bio Inc's expected revenue for the next quarter?
Nuvation Bio Inc's expected revenue is 26.95M.
What is Nuvation Bio Inc's price target?
Analysts forecast that Nuvation Bio Inc's price target is USD 10.00, with the highest forecast at USD 12.00 and the lowest forecast at USD 8.00.
How have Nuvation Bio IncNUVB's recent earnings per share performed?
The market expectation was USD 0.02, while Nuvation Bio IncNUVB's earnings per share (EPS) for the previous quarter was USD -0.11. EPS for the next quarter is expected at USD -0.18.
What is the analyst rating for Nuvation Bio Inc?
Based on the ratings of Nuvation Bio Inc's stock from 11 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.